MaxCyte, Inc. provided revenue guidance for the year 2022. The company expects revenue from core business (instruments and disposables to cell therapy and drug discovery customers) to grow between 22% and 25% over 2021. The company also expect SPL Program-related revenue to be approximately $4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
365 GBX | -0.54% | -2.67% | +3.55% |
May. 22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
May. 22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.55% | 486M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.05% | 65.01B | |
+15.38% | 53.02B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Year 2022